Objective: To estimate whether HIV-infected pregnant women were at an increased risk of hepatotoxicity when taking nevirapine (NVP)-containing regimens compared with HIV-infected pregnant women taking antiretroviral therapy (ART) not containing NVP.
Introduction
Nevirapine (NVP) use has been described as a risk factor for developing severe hepatotoxicity, particularly in women with CD4 þ cell counts above 250 cells/ml [1] [2] [3] [4] including pregnant women [5] [6] [7] . Reports of six maternal deaths secondary to fulminant hepatitis in previously antiretroviral therapy (ART)-naive women, four of whom had CD4 þ cell counts above 250 cells/ml [5, [7] [8] [9] , led to labeling changes by the manufacturer of NVP and a public health advisory by the US Food and Drug Administration (FDA) warning of these pregnancyrelated deaths [10, 11] . However, most previous studies examining the relationship of NVP and hepatotoxicity in pregnancy have come from case reports or have been limited to estimates among women using NVP only without a comparison group, which precludes an estimation of relative risk and limits interpretation of their results.
It is not clear whether continuous NVP use in pregnancy is associated with an increased risk of hepatotoxicity as compared to other ART. The goal of this study was to estimate whether HIV-infected pregnant women were at an increased risk of hepatotoxicity when taking NVP-containing regimens compared with ART not containing NVP.
Methods

Study population
The study population included HIV-infected pregnant women on ART from two cohorts in the United States: the Women and Infants Transmission Study (WITS) and the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) protocol P1025. Both WITS and IMPAACT P1025 are multicenter, prospective cohort studies of HIV-infected pregnant women [12, 13] . This analysis was limited to women enrolled after July 2002, when aspartate aminotransferase (AST) and alanine aminotransferase (ALT) data were collected prospectively. NVP exposure was dichotomized into use or no use and further categorized into three groups: ART naive (no prior ART exposure), ART chronic (taking ART at the time of conception) and ART restart (history of ART use, not taking at the time of conception). Women who received no ART or only intrapartum or postpartum treatment were excluded. Women with no aminotransferase data were also excluded.
Data collection
The period of observation began at the time of ART initiation if women started ART during pregnancy (ART naive and ART restart) or at the estimated date of conception in patients on ART at the time of conception (ART chronic). Data collection continued through their postpartum visit. Background data and baseline laboratory values collected are listed in Table 1 . Chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) was defined as the presence of either HCV antibody or HBV surface antigen. Both the WITS and P1025 protocols recorded AST and ALT data at the initiation of ART, every trimester, at time of delivery and at the postpartum visit.
Outcomes
ALTand AST levels were classified on the basis of changes relative to the upper limit of normal (ULN), according to the Division of AIDS toxicity guidelines for adults: grade 0, <1.25Â ULN; grade 1, 1.25-2.5Â ULN; grade 2, >2.5-5.0Â ULN; grade 3, >5.0-10.0Â ULN; and grade 4, >10.0Â ULN. The ULN for AST and ALT was individualized for each woman as per the institution's laboratory standard. If AST and ALT grades were discordant, the higher of the two was used for classification. Women with elevated pretreatment AST or ALT levels were graded on the basis of changes relative to their baseline: grade 0, <1.25Â baseline; grade 1, 1.25-2.5Â baseline; grade 2, >2.5-3.5Â baseline; grade 3, >3.5-5.0Â baseline; and grade 4, >5.0Â baseline [14] .
We investigated two hepatotoxicity outcomes: any liver enzyme elevation (LEE) (grade 1-4) and severe LEE (grade 3-4).
Statistical analysis
The baseline characteristics of the study population were compared according to NVP exposure. Differences in continuous variables were assessed using F tests, and differences in categorical variables were assessed using the Pearson chi-squared test and Fisher's exact chi-squared test.
Cox proportional hazards models were used to estimate the association between NVP use and LEE while controlling for potential confounders. Data were organized in the counting process style of input to model NVP and other covariates as time-dependent variables [15] . The only covariates not modeled as timedependent variables were ART exposure prior to followup, risk group for HIV transmission and race. Univariate analysis was first performed to screen for covariates to be included in multivariate analysis that were significant at a P value equal to 0.10. These covariates were then evaluated in a multivariate Cox regression model stratified by year of delivery and the study in which the woman was enrolled (WITS or P1025) to assess possible interaction. The SAS PHREG procedure (SAS version 8.2; SAS Institute Inc., Cary, North Carolina, USA) was used to perform these analyses.
A sample size of 1230 pregnant women (220 taking NVPcontaining regimens and 1010 taking non-NVP regimens) would provide 80% power to detect a minimum odds ratio (OR) of 1.7 for any hepatotoxicity and an OR of 3.8 for severe hepatotoxicity between pregnant patients taking NVP-containing regimens versus non-NVP regimens, assuming a 5% type I error.
Results
A total of 1358 women with ART exposure during pregnancy between July 2002 and June 2006 were considered for this study. After applying exclusion criteria, 1229 women were included in the study population, 218 (17.7%) of whom received NVP. Among the women receiving NVP, 137 (62.8%) were NVP naive. Sixty-one percent of the women were enrolled in IMPAACT P1025 (n ¼ 749), and 39% were enrolled in WITS (n ¼ 480). The baseline demographic and clinical characteristics are shown in Table 1 .
Twenty-nine women [13.3%, 95% confidence interval (CI) 9.1-18.5] who received NVP developed any LEE (grade 1 or higher) and one (0.5%, 95% CI 0.01-2.5) developed severe LEE (grade 3 or 4). Of the 1011 women on non-NVP regimens, 145 (14.3%, 95% CI 12.2-16.7) developed any LEE and 14 (1.4%, 95% CI 0.8-2.3) developed severe LEE. The only patient exposed to NVP who developed severe LEE was in the CD4 þ cell count above 250 cells/ml category. Of the 29 women exposed to NVP who developed any LEE, 21 (72.4%) had CD4 þ cell count above 250 cells/ml and seven (24.1%) had CD4 þ cell count below 250 cells/ml. One woman did not have CD4 þ cell count data available. These results are similar to the CD4 þ cell counts of women who developed LEE among the non-NVP group. Specifically, nine of the 14 women who developed severe LEE were in the CD4 þ cell count above 250 cells/ml category as compared with three of those in the CD4 þ cell count below 250 cells/ml category (two did not have CD4 þ cell count data available). Of the 145 women not exposed to NVPcontaining regimens who developed any LEE, 111 (77%) had CD4 þ cell count above 250 cells/ml and 22 (15%) had CD4 þ cell count below 250 cells/ml. Twelve did not have CD4 þ cell count data available. There were no maternal deaths. The median time from initiation of therapy to any LEE in patients treated with NVP or other ART during pregnancy was 163 and 157 days, respectively.
Univariate analysis showed that LEE was significantly associated with chronic hepatitis, alcohol use, intravenous (i.v.) drug use, thrombocytopenia (<150 000 ml), immunological stage 3, baseline elevated liver enzyme and history of Centers for Disease Control and Prevention (CDC) class C events at a P value equal to 0.10. CD4 þ cell count above 250 cells/ml and both ART and NVP naive were not significantly associated with LEE. Table 2) . Each model provides a different reference group against which the other exposures were compared. For example, model 4 uses women who were treated with NVP for the first time in pregnancy (NVP positive, NVP naive) as the reference group. The relative risk for developing LEE in women who were also treated with NVP in pregnancy, but had previously been exposed to NVP (NVP positive, NVP exposed), was 0.97 relative to the reference group. Although CD4 þ cell count was not found to be significantly associated with LEE in the univariate analysis, we included a separate model examining LEE in women with CD4 þ cell count above 250 cells/ml stratified by NVP exposure due to unique concerns of hepatotoxicity in this population [5, 7, 16] (model 5) . When CD4 þ cell count above 250 cells/ml was included in the multivariate analysis for the other models, the results continued to demonstrate no significant difference in LEE between the reference group and the comparison groups. In all the models, NVP use during pregnancy was not significantly associated with either any or severe LEE.
Multivariate Cox regression analysis estimated associations between various categories of NVP and ART exposures and any LEE (
Discussion
The frequency of both grade 1 or higher (13.3%, 95% CI 9.1-18.5) and grade 3 or higher hepatotoxicity (0.5%, 95% CI 0.01-2.5) in pregnant women using NVP in our study is less than that reported in other studies. Hitti et al. [5] reported the phase I results of the PACTG 1022 trial, which found a 29.4% rate of treatment discontinuation among the 17 pregnant patients taking NVP for suspected hepatotoxicity. However, one of the five patients who discontinued treatment developed only right upper quadrant pain with no LEE. This may reflect provider ascertainment bias in this nonblinded intervention study, leading to premature discontinuation of therapy in the NVP group secondary to a preexisting concern that they were at an increased risk for developing hepatotoxicity. The authors acknowledge in this study that the small sample size may have resulted in an overestimation of the actual incidence of hepatotoxicity. In a retrospective study, Lyons et al. [7] described grade 1 or higher LEE occurring in 34.1% of 85 women using NVP. These two studies and others [17] have reported a 6.5-11.8% rate of grade 3 or a higher hepatotoxicity as compared to only 0.5% (95% CI 0.01-2.5) in our study. Our lower rates of both grade 1þ and grade 3þ LEE are more similar to results reported in studies from Thailand [18] , Brazil [19] , Mozambique [16] and London [20] . Although ethnic differences have been suggested as a possible factor in these discordant findings [20] , our study population was very similar to the ethnic composition of the PACTG 1022 study.
We observed no maternal deaths in our study of 1229 pregnant women on ART. This included 218 women taking NVP-containing regimens, 137 (62.8%) of whom were NVP naive. This is somewhat in contrast to reports of six maternal deaths associated with continuous NVP use in pregnancy [5, 8, 9] . Reporting bias may play a role in this apparent difference in mortality, as only one of these six deaths occurred in the setting of a prospective trial, whereas the remainders were case reports or personal communications. We also did not find an association between CD4 þ cell count above 250 cells/ml and risk of hepatotoxicity in patients taking NVP in both univariate and multivariate analyses. The lack of evidence of an effect of CD4 þ cell count on LEE is consistent with the 112 AIDS 2010, Vol 24 No 1 largest review on NVP and hepatotoxicity, which also was unable to demonstrate a CD4 þ cell count cutoff in women that was associated with an increased risk of LEE [3] . Individual genetic susceptibility may play an important role in the development of hepatotoxicity in relation to CD4 þ cell count [21] .
Our study has potential limitations. First, confounding by indication may have occurred if clinicians avoided prescribing NVP to women at greatest risk for developing hepatotoxicity, leading to an underestimation of risk in these patients. In our study, women using NVP during pregnancy were significantly less likely to be NVP naive and thus may have differentially included women with tolerance to the hepatic effects of NVP. Still, the control group did generally have similar background characteristics to the NVP group, including baseline CD4 þ cell counts. In addition, the majority of the data in this study were obtained prior to the FDA public advisory and NVP manufacturer's labeling changes (2005) warning against potential increased risks of hepatotoxicity, making it less likely that these concerns biased the conclusions of this study. Finally, we attempted to control for confounding by indication through consideration of several potential confounding variables.
Another potential limitation was that we were unable to differentiate possible obstetrical causes of LEE from druginduced hepatotoxicity. As such, it is reasonable to assume that a group of the patients in our study had LEE independent of their ART exposure. A 15-month prospective study [22] of 4377 deliveries found a 3% incidence of LEE during pregnancy. Pregnancy-specific causes such as preeclampsia comprised the majority of these cases (67%), whereas drug toxicity accounted for less than 2% of the pregnancies with elevated liver enzymes.
Other studies have shown that HIV-infected pregnant women are not at significantly greater risk of developing these pregnancy conditions most often associated with liver dysfunction [23] . Considering the incidence of LEE in our study (14%), which was significantly higher than in the study by Ch'ng et al. [22] (3%), it is reasonable to assume that the majority of the additional LEE was associated with ART use, although a causal association could not be proven.
In regards to the disproportionate contribution of women from P1025, a sensitivity analysis was performed that stratified the multivariate analysis by study (WITS and P1025), and no significant differences were seen from the combined analysis. This likely reflects the fact that the WITS and P1025 trials were both prospective, observational studies that are very similar on multiple levels such as inclusion and exclusion criteria, population characteristics and frequency of study visits [12, 13] . In addition, by limiting the WITS population to those enrolled after 2002, we ensured that the schedule for liver function test (LFT) monitoring would be the same between the two trials and that the studies would cover the same calendar time frame.
Strengths of this study include the large number of women enrolled, which provided statistical power to detect clinically important increases in risk, the inclusion of a reference group of HIV-infected pregnant women not on ART and the prospective and standardized nature of the data collection. Even if pregnant women are uniquely at an increased risk for hepatotoxicity, our data suggest that this risk is not substantially higher with NVP exposure as compared to other ART. The risk of hepatotoxicity associated with NVP use may be less than other studies have estimated and clinicians have feared. Specifically, the 95% CI for the adjusted relative risk of any LEE among NVP-unexposed versus NVP-exposed women ranged from 0.64 to 1.57, which suggests that a substantial increase in risk of LEE with NVP use in pregnancy is unlikely ( Table 2) .
We would still exercise caution when administering any antiretroviral medication during pregnancy, with close clinical surveillance for symptoms of hepatotoxicity and laboratory monitoring for LEE, especially when initiating or altering a regimen. As with the decision to prescribe any medication, healthcare providers must carefully consider the risks and benefits of specific ART regimens and individualize therapy to each patient.
